Search

Your search keyword '"Glass, Bertram"' showing total 413 results
Start Over Author "Glass, Bertram" Search Limiters Available in Library Collection
413 results on '"Glass, Bertram"'

1. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years

Author

Berning, Philipp, Fekom, Mathilde, Ngoya, Maud, Goldstone, Anthony H., Dreger, Peter, Montoto, Silvia, Finel, Hervé, Shumilov, Evgenii, Chevallier, Patrice, Blaise, Didier, Strüssmann, Tim, Carpenter, Ben, Forcade, Edouard, Castilla-Llorente, Cristina, Trneny, Marek, Ghesquieres, Hervé, Capria, Saveria, Thieblemont, Catherine, Blau, Igor Wolfgang, Meijer, Ellen, Broers, Annoek E. C., Huynh, Anne, Caillot, Denis, Rösler, Wolf, Nguyen Quoc, Stephanie, Bittenbring, Jörg, Nagler, Arnon, Galimard, Jacques-Emmanuel, Glass, Bertram, Sureda, Anna, and Schmitz, Norbert

Published
2024
Full Text
View/download PDF

2. PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT

Author

Montoro, Juan, Ngoya, Maud, Kulagin, Alexander, Giebel, Sebastian, Broers, Annoek E. C., Bramanti, Stefania, Halahleh, Khalid, Pérez-Simón, Jose A., Solano, Carlos, Ozcelik, Tulay, Blaise, Didier, Sanz, Jaime, Henriques, Marta, Peffault de Latour, Régis, Martino, Rodrigo, Scheid, Christof, Fox, Laura, Gromek, Tomasz, Jurado, Manuel, Sakellari, Ioanna, Van Gorkom, Gwendolyn, Matteucci, Paola, Nagler, Arnon, Koc, Yener, and Glass, Bertram

Published
2024
Full Text
View/download PDF

3. Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study

Author

Renders, Simon, Ngoya, Maud, Finel, Herve, Rubio, Marie-Thérèse, Townsend, William, Schroers, Roland, Novak, Urban, Schaap, Nicolaas, Aljurf, Mahmoud, Helbig, Grzegorz, Collin, Matthew, Kobbe, Guido, Huynh, Anne, Pérez-Simón, José Antonio, Bloor, Adrian, Ghesquieres, Hervé, Sureda, Anna, Schmitz, Norbert, Glass, Bertram, and Dreger, Peter

Published
2024
Full Text
View/download PDF

4. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Author

Thieblemont, Catherine, Altmann, Bettina, Frontzek, Fabian, Renaud, Loïc, Chartier, Loic, Ketterer, Nicolas, Récher, Christian, Poeschel, Viola, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Morschhauser, Franck, Glass, Bertram, Mounier, Nicolas, Tilly, Herve, Rosenwald, Andreas, Ott, German, Lenz, Georg, Molina, Thierry, Ziepert, Marita, and Schmitz, Norbert

Published
2023
Full Text
View/download PDF

5. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Author

Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, and Kamdar, Manali

Published
2023
Full Text
View/download PDF

9. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Author

Bethge, Wolfgang A., Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Marie, Wulf, Gerald G., Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Fante, Matthias A., Schroers, Roland, Bayir, Lale, Borchmann, Peter, Buecklein, Veit, Hasenkamp, Justin, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

10. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

Author

Hamadani, Mehdi, Ngoya, Maud, Sureda, Anna, Bashir, Qaiser, Litovich, Carlos Alejandro, Finel, Hervé, Chen, Yue, Boumendil, Ariane, Zain, Jasmine, Castagna, Luca, Cashen, Amanda F., Blaise, Didier, Shadman, Mazyar, Pastano, Rocco, Khimani, Farhad, Arat, Mutlu, Dietrich, Sascha, Schmitz, Norbert, Glass, Bertram, Kharfan-Dabaja, Mohamed A., Corradini, Paolo, Sauter, Craig S., Montoto, Silvia, Kwon, Mi, Herrera, Alex F., and Dreger, Peter

Published
2022
Full Text
View/download PDF

11. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Author

Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva, Acker, Fabian, Fuhrmann, Stephan, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caillé, Léandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter, and Dietrich, Sascha

Published
2021
Full Text
View/download PDF

12. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Author

Pérez-Simón, José A. [0000-0003-3616-6101], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Montoro, Juan, Boumendil, Ariane, Finel, Hervé, Bramanti, Stefania, Castagna, Luca, Blaise, Didier, Dominietto, Alida, Kulagin, Aleksandr, Yakoub-Agha, Ibrahim, Tbakhi, Abdelghani, Solano, Carlos, Giebel, Sebastian, Gulbas, Zafer, López-Corral, Lucía, Pérez-Simón, José A., Diez-Martin, José L., Sanz, Jaime, Farina, Lucia, Koc, Yener, Socié, Gerard, Arat, Mutlu, Jurado, Manuel, Bermúdez, Arancha, Labussiere-Wallet, Helene, Villalba, Marta, Ciceri, Fabio, Martínez, Carmen, Nagler, Arnon, Sureda, Anna, Glass, Bertram, Pérez-Simón, José A. [0000-0003-3616-6101], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Montoro, Juan, Boumendil, Ariane, Finel, Hervé, Bramanti, Stefania, Castagna, Luca, Blaise, Didier, Dominietto, Alida, Kulagin, Aleksandr, Yakoub-Agha, Ibrahim, Tbakhi, Abdelghani, Solano, Carlos, Giebel, Sebastian, Gulbas, Zafer, López-Corral, Lucía, Pérez-Simón, José A., Diez-Martin, José L., Sanz, Jaime, Farina, Lucia, Koc, Yener, Socié, Gerard, Arat, Mutlu, Jurado, Manuel, Bermúdez, Arancha, Labussiere-Wallet, Helene, Villalba, Marta, Ciceri, Fabio, Martínez, Carmen, Nagler, Arnon, Sureda, Anna, and Glass, Bertram

Abstract

Post-transplantation cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies examining the impact of this GVHD prophylaxis when different donor types are used in patients with Hodgkin lymphoma (HL). This study compared the outcomes of patients with HL undergoing HSCT from HLA-matched donors, including matched sibling donors (MSDs) and matched unrelated donors (MUDs), and haploidentical donors, using PTCy as the GVHD prophylaxis approach in all cohorts. We retrospectively compared outcomes of allo-HSCT from 166 HLA-matched donors (96 sibling and 70 unrelated donors) and 694 haploidentical donors using PTCy-based GVHD prophylaxis in patients with HL registered in the European Society for Blood and Marrow Transplantation database from 2010 to 2020. Compared to HLA-matched HSCT, haploidentical donor HSCT was associated with a significantly lower rate of platelet engraftment (86% versus 94%; P < .001) and a higher rate of grade II-IV acute GVHD (34% versus 24%; P = .01). The 2-year cumulative incidence of nonrelapse mortality (NRM) was significantly lower in the HLA-matched cohort compared to the haploidentical cohort (10% versus 18%; P = .02), resulting in a higher overall survival (OS) rate (82% versus 70%; P = .002). There were no significant differences between the 2 cohorts in terms of relapse, progression-free survival, or GVHD-free relapse-free survival. In multivariable analysis, haploidentical HSCT was associated with an increased risk of grade II-IV acute GVHD and NRM and worse OS compared to HLA-matched HSCT. Our findings suggest that in the context of PTCy-based GVHD prophylaxis, transplantation from HLA-matched donors appears to be a more favorable option compared to haploidentical HSCT.

Published
2024

13. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

Author

Mussetti, Alberto, Kanate, Abraham S., Wang, Tao, He, Meilun, Hamadani, Mehdi, Finel, Hervé, Sr., Boumendil, Ariane, Sr., Glass, Bertram, Castagna, Luca, Dominietto, Alida, McGuirk, Joseph, Blaise, Didier, Gülbas, Zafer, Diez-Martin, Jose, Marsh, Steven G.E., Paczesny, Sophie, Gadalla, Shahinaz M., Dreger, Peter, Zhang, Mei-Jie, Spellman, Stephen R., Lee, Stephanie J., Bolon, Yung-Tsi, and Sureda, Anna

Published
2023
Full Text
View/download PDF

14. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Author

Schubert, Maria-Luisa, primary, Bethge, Wolfgang A., additional, Ayuk, Francis A., additional, von Bonin, Malte, additional, Vucinic, Vladan, additional, Wagner-Drouet, Eva Marie, additional, Subklewe, Marion, additional, Baldus, Claudia D., additional, Glass, Bertram, additional, Marks, Reinhard, additional, Mougiakakos, Dimitrios, additional, Schroers, Roland, additional, Stelljes, Matthias, additional, Topp, Max S., additional, Wulf, Gerald, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2023
Full Text
View/download PDF

15. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Koenecke, Christian, additional, Polge, Emmanuelle, additional, Sanderson, Robin, additional, Yakoub-Agha, Ibrahim, additional, Fegueux, Nathalie, additional, Daskalakis, Michael, additional, Collin, Matthew, additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Schanz, Urs, additional, Bloor, Adrian, additional, Ganser, Arnold, additional, Besley, Caroline, additional, Wulf, Gerald G., additional, Novak, Urban, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Basak, Grzegorz W., additional, Chabannon, Christian, additional, Sureda, Anna, additional, Glass, Bertram, additional, and Peric, Zinaida, additional

Published
2023
Full Text
View/download PDF

16. S225: ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

Author

Berning, Philipp, primary, Schmitz, Norbert, additional, Ngoya, Maud, additional, Finel, Hevé, additional, Boumendil, Ariane, additional, Wang, Fengrong, additional, Huang, Xiaojun, additional, Hermine, Olivier, additional, Philippe, Laure, additional, Couronné, Lucile, additional, Jaccard, Arnaud, additional, Liu, Dai-Hong, additional, Wu, Depei, additional, Reinhardt, Christian, additional, Chalandon, Yves, additional, Wagner-Drouet, Eva, additional, Kwon, MI, additional, Zhang, XI, additional, Carpenter, Ben, additional, Yakoub-Agha, Ibrahim, additional, Wulf, Gerald, additional, Jimenez, Francisco Lopez, additional, Sanz, Jaime, additional, Wallet, Hélène Labussiere, additional, Shimoni, Avichai, additional, Dreger, Peter, additional, Sureda, Anna, additional, Kim, Won-Seog, additional, and Glass, Bertram, additional

Published
2023
Full Text
View/download PDF

18. PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA

Author

Westin, Jason, primary, Jacobson, Caron, additional, Chavez, Julio C, additional, Sureda, Anna, additional, Morschhauser, Franck, additional, Glass, Bertram, additional, Dickinson, Michael, additional, Davies, Andrew J., additional, Flinn, Ian W., additional, Maloney, David, additional, Chamuleau, Martine, additional, Tees, Michael, additional, Xue, Allen, additional, Shahani, Shilpa, additional, Nikolajeva, Olga, additional, Kang, Janet, additional, Kaplan, Aida, additional, Schupp, Marco, additional, Miao, Harry, additional, and Rich, Elizabeth Shima, additional

Published
2023
Full Text
View/download PDF

19. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Author

Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Jürgen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yáñez, Lucrecia, Beguin, Yves, Sill, Heinz, Scheid, Christof, Stelljes, Matthias, Ganser, Arnold, Zachée, Pierre, Selleslag, Dominik, de Witte, Theo, Robin, Marie, and Kröger, Nicolaus

Published
2017
Full Text
View/download PDF

20. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation

Author

Fuerst, Daniel, Neuchel, Christine, Niederwieser, Dietger, Bunjes, Donald, Gramatzki, Martin, Wagner, Eva, Wulf, Gerald, Glass, Bertram, Pfreundschuh, Michael, Einsele, Hermann, Arnold, Renate, Stuhler, Gernot, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Kaufmann, Martin, Wattad, Mohammed, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Mytilineos, Daphne, Tsamadou, Chrysanthi, Mueller, Carlheinz, Schrezenmeier, Hubert, and Mytilineos, Joannis

Published
2016
Full Text
View/download PDF

21. Treosulfan compared with <scp>reduced‐intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich, Stelljes, Matthias, Reményi, Péter, Wagner‐Drouet, Eva‐Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stölzel, Friedrich, Junghanß, Christian, Labussiere‐Wallet, Hélène, Schaefer‐Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socié, Gérard, Holler, Ernst, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, La Rocca, Ursula, Finke, Jürgen, Benedetti, Fabio, Pichlmeier, Uwe, Klein, Anja, Baumgart, Joachim, Markiewicz, Miroslaw, and Rocca, Ursula La

Subjects
Leukemia, Myeloid, Acute, Transplantation Conditioning, Myelodysplastic Syndromes, Medizin, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Prospective Studies, Hematology, Middle Aged, Busulfan, Vidarabine, Aged
Abstract

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged >= 50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m(2) IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

Published
2022

22. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Koenecke, Christian, additional, Polge, Emmanuelle, additional, Kuhnl, Andrea, additional, Fegueux, Nathalie, additional, Daskalakis, Michael, additional, Kröger, Nicolaus, additional, Dreger, Peter, additional, Besley, Caroline, additional, Schanz, Urs, additional, Bloor, Adrian, additional, Ganser, Arnold, additional, Forcade, Edouard, additional, Corral, Lucia López, additional, Passweg, Jakob R, additional, Novak, Urban, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Basak, Grzegorz W, additional, Chabannon, Christian, additional, Sureda, Anna, additional, Averbuch, Dina, additional, Glass, Bertram, additional, de la Camara, Rafael, additional, and Peric, Zinaida, additional

Published
2023
Full Text
View/download PDF

23. Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Author

Abramson, Jeremy S., primary, Solomon, Scott R., additional, Arnason, Jon, additional, Johnston, Patrick B., additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew, additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, Stepan, Lara, additional, Ogasawara, Ken, additional, and Kamdar, Manali, additional

Published
2023
Full Text
View/download PDF

24. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma:primary analysis of the phase 3 TRANSFORM study

Author

Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali, Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, and Kamdar, Manali

Abstract

This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor–positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351.

Published
2023

25. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Author

Snowden, John A., Sánchez-Ortega, Isabel, Corbacioglu, Selim, Basak, Grzegorz W., Chabannon, Christian, de la Camara, Rafael, Dolstra, Harry, Duarte, Rafael F., Glass, Bertram, Greco, Raffaella, Lankester, Arjan C., Mohty, Mohamad, Neven, Bénédicte, de Latour, Régis Peffault, Pedrazzoli, Paolo, Perić, Zinaida, Yakoub-Agha, Ibrahim, Sureda, Anna, Kröger, Nicolaus, and UAM. Departamento de Medicina

Subjects
Transplantation, Neoplasms / therapy, Medicina, Haematopoietic cell transplantation (HCT), Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Hematologic Diseases / therapy, Hematopoietic Stem Cell Transplantation, Hematology, Europe, Immune System Diseases / therapy, Immune disorders, HCT, Humans, Haematological diseases, Solid tumours, EBMT
Abstract

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered in conjunction with the risk of the disease, risk of HCT procedure and non-transplant strategies, including evolving cellular therapies. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE accreditation standards to maintain quality in clinical and laboratory components of practice, including benchmarking of survival outcomes. Since the last edition, the COVID-19 pandemic has affected clinical decision making and activity across indications. Although the full impact of the pandemic is yet to be determined, we recommend that decision making across indications is delivered with ongoing reference to EBMT and national COVID-19 guidance, in accordance with current local conditions.

Published
2022

26. Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Author

Berning, Philipp, primary, Ngoya, Maud, additional, Schmitz, Norbert, additional, Finel, Hervé, additional, Boumendil, Ariane, additional, Kim, Won-Seog, additional, Wang, Fengrong, additional, Huang, Xiao-jun, additional, Hermine, Olivier, additional, Philippe, Laure, additional, Couronne, Lucile, additional, Jaccard, Arnaud, additional, Liu, Daihong, additional, Wu, Depei, additional, Reinhardt, Hans Christian, additional, Chalandon, Yves, additional, Wagner, Eva Maria, additional, Kwon, Mi, additional, Zhang, Xi, additional, Carpenter, Ben, additional, Yakoub-Agha, Ibrahim, additional, Wulf, Gerald, additional, López Jiménez, Javier, additional, Sanz, Jaime, additional, Labussière-Wallet, Hélène, additional, Shimoni, Avichai, additional, Dreger, Peter, additional, Sureda, Anna, additional, and Glass, Bertram, additional

Published
2022
Full Text
View/download PDF

27. Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Author

Rius Sansalvador, Blanca, primary, Mussetti, Alberto, additional, Moreno, Victor, additional, Peczynski, Christophe, additional, Polge, Emmanuelle, additional, Kröger, Nicolaus, additional, Blaise, Didier, additional, Peffault de Latour, Régis, additional, Kulagin, Alexander D., additional, Mousavi, Ashrafsadat, additional, Stelljes, Matthias, additional, Hamladji, Rose-Marie, additional, Bornhäuser, Martin, additional, Salmenniemi, Urpu, additional, Sengeloev, Henrik, additional, Forcade, Edouard, additional, Platzbecker, Uwe, additional, Reményi, Péter, additional, Angelucci, Emanuele, additional, Chevallier, Patrice, additional, Yakoub-Agha, Ibrahim, additional, Craddock, Charles, additional, Ciceri, Fabio, additional, Schroeder, Thomas, additional, Aljurf, Mahmoud, additional, Moiseev, Ivan, additional, Penack, Olaf, additional, Schoemans, Helene, additional, Mohty, Mohamad, additional, Glass, Bertram, additional, Sureda, Anna, additional, Basak, Grzegorz W, additional, and Peric, Zinaida, additional

Published
2022
Full Text
View/download PDF

28. Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Author

Abramson, Jeremy S., primary, Solomon, Scott R., additional, Arnason, Jon E., additional, Johnston, Patrick B., additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew A., additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, and Kamdar, Manali, additional

Published
2022
Full Text
View/download PDF

29. Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Koenecke, Christian, additional, Polge, Emmanuelle, additional, Potter, Victoria, additional, Yakoub-Agha, Ibrahim, additional, Fegueux, Nathalie, additional, Daskalakis, Michael, additional, Collin, Matthew P., additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Schanz, Urs, additional, Bloor, Adrian, additional, Ganser, Arnold, additional, Besley, Caroline, additional, Wulf, Gerald, additional, Novak, Urban, additional, Moiseev, Ivan, additional, Schoemans, Helene, additional, Basak, Grzegorz W, additional, Chabannon, Christian, additional, Sureda, Anna, additional, Glass, Bertram, additional, and Peric, Zinaida, additional

Published
2022
Full Text
View/download PDF

30. Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT

Author

Paviglianiti, Annalisa, primary, Mussetti, Alberto, additional, Ngoya, Maud, additional, Boumendil, Ariane, additional, Gulbas, Zafer, additional, Ciceri, Fabio, additional, Bonifazi, Francesca, additional, Russo, Domenico, additional, Fegueux, Nathalie, additional, Stölzel, Friedrich, additional, Bulabois, Claude-Eric, additional, Socie, Gerard, additional, Forcade, Edouard, additional, Solano, Carlos, additional, Finel, Hervé, additional, Robinson, Stephen, additional, Montoto, Silvia, additional, and Glass, Bertram, additional

Published
2022
Full Text
View/download PDF

31. CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Author

Glass, Bertram, primary, Sureda, Anna, additional, Boumendil, Ariane, additional, Dreger, Peter, additional, Corradini, Paolo, additional, Ram, Ron, additional, Kroeger, Nicolaus, additional, Castagna, Luca, additional, Pabst, Thomas, additional, Kwon, Mi, additional, Wulf, Gerald, additional, Martín García-Sancho, Alejandro, additional, Solano, Carlos, additional, Stelljes, Matthias, additional, Reinhardt, Hans Christian, additional, Rubio, Marie Thérèse, additional, Malladi, Ram, additional, Blaise, Didier, additional, Besley, Caroline, additional, Forcade, Edouard, additional, von Bonin, Malte, additional, Finke, Jürgen, additional, Hilgendorf, Inken, additional, Martínez-López, Joaquín, additional, Perez-Simon, Jose A., additional, Bethge, Wolfgang, additional, and Schmitz, Norbert, additional

Published
2022
Full Text
View/download PDF

32. Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Koenecke, Christian, additional, Polge, Emmanuelle, additional, Potter, Victoria, additional, Fegueux, Nathalie, additional, Daskalakis, Michael, additional, Kröger, Nicolaus, additional, Dreger, Peter, additional, Besley, Caroline, additional, Schanz, Urs, additional, Bloor, Adrian, additional, Ganser, Arnold, additional, Forcade, Edouard, additional, Corral, Lucía López, additional, Passweg, Jakob, additional, Novak, Urban, additional, Moiseev, Ivan, additional, Schoemans, Helene, additional, Basak, Grzegorz W., additional, Chabannon, Christian, additional, Sureda, Anna, additional, Averbuch, Diana, additional, Glass, Bertram, additional, De La Camara, Rafael, additional, and Peric, Zinaida, additional

Published
2022
Full Text
View/download PDF

33. Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Author

Martinez Munoz, Maria Carmen, primary, Bastos-Oreiro, Mariana, additional, Boumendil, Ariane, additional, Finel, Hervé, additional, Bazarbachi, Ali, additional, Alzahrani, Mohsen, additional, Illes, Arpad, additional, Blaise, Didier, additional, Sakellar, Ioanna, additional, Solano, Carlos, additional, Pulsoni, Alessandro, additional, Zuckerman, Tsila, additional, Durakovic, Nadira, additional, Castagna, Luca, additional, Sica, Simona, additional, Guidez, Stéphanie, additional, Bourhis, Jean-Henri, additional, García-Sanz, Ramón, additional, Cemm Ar, Muhlis, additional, Stamatoulas Bastard, Aspasia, additional, Briones, Javier, additional, Aktar, Saad, additional, Ram, Ron, additional, Heras, Inmaculada, additional, Rubio, Marie Thérèse, additional, Petrini, Mario, additional, Ojeda-Uribe, Mario, additional, Glass, Bertram, additional, and Sureda, Anna, additional

Published
2022
Full Text
View/download PDF

34. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial

Author

Bornhäuser, Martin, Schliemann, Christoph, Schetelig, Johannes, Röllig, Christoph, Kramer, Michael, Glass, Bertram, Platzbecker, Uwe, Burchert, Andreas, Hänel, Mathias, Müller, Lutz P., Klein, Stefan, Bug, Gesine, Beelen, Dietrich, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schmid, Christoph, Jost, Edgar, Lenz, Georg, Tischer, Johanna, Spiekermann, Karsten, Pfirrmann, Markus, Serve, Hubert, Stölzel, Friedrich, Alakel, Nael, Middeke, Jan Moritz, Thiede, Christian, Ehninger, Gerhard, Berdel, Wolfgang E., and Stelljes, Matthias

Subjects
Cancer Research, Oncology, Medizin
Abstract

ImportanceThe ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.ObjectiveTo explore the optimal therapy for patients with intermediate-risk AML after first complete remission.Design, Settings, and ParticipantsThis investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)–matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.InterventionsPatients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related).Main Outcomes and MeasuresEnd points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.ResultsA total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.Conclusions and RelevancePrimary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.Trial RegistrationClinicalTrials.gov Identifier: NCT01246752

Published
2023

35. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT

Author

Santoro, Nicole, Labopin, Myriam, Giannotti, Federica, Ehninger, Gerard, Niederwieser, Dietger, Brecht, Arne, Stelljes, Matthias, Kröger, Nicolaus, Einsele, Herman, Eder, Matthias, Hallek, Michael, Glass, Bertram, Finke, Jürgen, Ciceri, Fabio, Mohty, Mohamad, Ruggeri, Annalisa, and Nagler, Arnon

Published
2018
Full Text
View/download PDF

36. Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study

Author

Gagelmann, Nico, primary, Wulf, Gerald Georg, additional, Duell, Johannes, additional, Glass, Bertram, additional, Heteren, Pearl van, additional, von Tresckow, Bastian, additional, Fischer, Monika, additional, Penack, Olaf, additional, Ayuk, Francis A, additional, Einsele, Hermann, additional, Holtick, Udo, additional, Thomson, Julia, additional, Dreger, Peter, additional, and Kröger, Nicolaus, additional

Published
2022
Full Text
View/download PDF

37. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich W., primary, Stelljes, Matthias, additional, Reményi, Péter, additional, Wagner‐Drouet, Eva‐Maria, additional, Dreger, Peter, additional, Bethge, Wolfgang, additional, Ciceri, Fabio, additional, Stölzel, Friedrich, additional, Junghanß, Christian, additional, Labussiere‐Wallet, Hélène, additional, Schaefer‐Eckart, Kerstin, additional, Grigoleit, Goetz U., additional, Scheid, Christof, additional, Patriarca, Francesca, additional, Rambaldi, Alessandro, additional, Niederwieser, Dietger, additional, Hilgendorf, Inken, additional, Russo, Domenico, additional, Socié, Gérard, additional, Holler, Ernst, additional, Glass, Bertram, additional, Casper, Jochen, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Bieniaszewska, Maria, additional, Stuhler, Gernot, additional, Verbeek, Mareike, additional, La Rocca, Ursula, additional, Finke, Jürgen, additional, Benedetti, Fabio, additional, Pichlmeier, Uwe, additional, Klein, Anja, additional, Baumgart, Joachim, additional, and Markiewicz, Miroslaw, additional

Published
2022
Full Text
View/download PDF

39. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Author

Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)

Subjects
0301 basic medicine, Male, cd52 expression, Cancer Research, epstein-barr-virus, medicine.medical_treatment, CHOP, Gastroenterology, PROPHYLAXIS, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Significant risk, Alemtuzumab, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Hematology, lymphoproliferative disorders, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, 3. Good health, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Toxicity, PHASE-II, Female, medicine.drug, medicine.medical_specialty, prognostic-factors, Medication Adherence, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, non-hodgkin-lymphoma, Cyclophosphamide, Aged, Chemotherapy, therapy, business.industry, Lymphoma, T-Cell, Peripheral, DETUDE-DES-LYMPHOMES, medicine.disease, Survival Analysis, Peripheral T-cell lymphoma, 030104 developmental biology, Doxorubicin, Prednisone, business
Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021

40. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich W., Stelljes, Matthias, Remenyi, Peter, Wagner-Drouet, Eva-Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stoelzel, Friedrich, Junghanss, Christian, Labussiere-Wallet, Helene, Schaefer-Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socie, Gerard, Holler, Ernst, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, La Rocca, Ursula, Finke, Juergen, Benedetti, Fabio, Pichlmeier, Uwe, Klein, Anja, Baumgart, Joachim, Markiewicz, Miroslaw, Beelen, Dietrich W., Stelljes, Matthias, Remenyi, Peter, Wagner-Drouet, Eva-Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stoelzel, Friedrich, Junghanss, Christian, Labussiere-Wallet, Helene, Schaefer-Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socie, Gerard, Holler, Ernst, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, La Rocca, Ursula, Finke, Juergen, Benedetti, Fabio, Pichlmeier, Uwe, Klein, Anja, Baumgart, Joachim, and Markiewicz, Miroslaw

Abstract

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged >= 50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m(2) IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

Published
2022

41. Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS)

Author

Stelljes, Matthias, primary, Trenschel, Rudolf, additional, Beelen, Dietrich Wilhelm, additional, Markiewicz, Miroslaw, additional, Wagner, Eva Maria, additional, Bethge, Wolfgang, additional, Remenyi, Peter, additional, Niederwieser, Dietger, additional, Grigoleit, Goetz, additional, Schaefer-Eckart, Kerstin, additional, Stölzel, Friedrich, additional, Ciceri, Fabio, additional, Dreger, Peter, additional, Junghanß, Christian, additional, Holler, Ernst, additional, Rambaldi, Alessandro, additional, Russo, Domenico, additional, Verbeek, Mareike, additional, Casper, Jochen, additional, Patriarca, Francesca, additional, Bieniaszewska, Maria, additional, Glass, Bertram, additional, Scheid, Christoph, additional, Basara, Nadezda, additional, Finke, Jürgen, additional, Hilgendorf, Inken, additional, Labussière-Wallet, Hélène, additional, Stuhler, Gernot, additional, and Schroeder, Thomas, additional

Published
2022
Full Text
View/download PDF

42. Haploidentical Versus Matched Unrelated Donor Transplants for Lymphomas Using Post-Transplant Cyclophosphamide: A Joint CIBMTR/EBMT Study

Author

Mussetti, Alberto, primary, Kanate, Abraham S., additional, Wang, Tao, additional, He, Meilun, additional, Hamadani, Mehdi, additional, Finel, Herve, additional, Boumendil, Ariane, additional, Glass, Bertram, additional, Castagna, Luca, additional, Blaise, Didier, additional, Marsh, Steven GE, additional, Paczesny, Sophie, additional, Gadalla, Shahinaz M, additional, Dreger, Peter, additional, Spellman, Stephen, additional, Lee, Stephanie J, additional, Bolon, Yung-Tsi, additional, and Sureda, Anna, additional

Published
2022
Full Text
View/download PDF

43. Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Author

Kamdar, Manali, primary, Solomon, Scott R., additional, Arnason, Jon E., additional, Johnston, Patrick B, additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco J, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew, additional, Maloney, David G., additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, Stepan, Lara, additional, Ogasawara, Ken, additional, Mack, Timothy, additional, and Abramson, Jeremy S., additional

Published
2022
Full Text
View/download PDF

44. Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial

Author

Stölzel, Friedrich, primary, Stelljes, Matthias, additional, Beelen, Dietrich Wilhelm, additional, Markiewicz, Miroslaw, additional, Remenyi, Peter, additional, Dreger, Peter, additional, Ciceri, Fabio, additional, Wagner-Drouet, Eva-Maria, additional, Junghanss, Christian, additional, Scheid, Christoph, additional, Patriarca, Francesca, additional, Socié, Gerard, additional, Hilgendorf, Inken, additional, Rambaldi, Alessandro, additional, Schaefer-Eckart, Kerstin, additional, Russo, Domenico, additional, Grigoleit, Goetz, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Glass, Bertram, additional, Stuhler, Gernot, additional, Bieniaszewska, Maria, additional, Casper, Jochen, additional, Holler, Ernst, additional, Benedetti, Fabio, additional, Iori, Anna Paola, additional, Trenschel, Rudolf, additional, and Bethge, Wolfgang, additional

Published
2022
Full Text
View/download PDF

45. Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Author

Kamdar, Manali, primary, Solomon, Scott R., additional, Arnason, Jon E., additional, Johnston, Patrick B., additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim G.N.J., additional, Hernandez-Ilizaliturri, Francisco J., additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew A., additional, Maloney, David G., additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, Stepan, Lara, additional, Ogasawara, Ken, additional, Mack, Timothy, additional, and Abramson, Jeremy S., additional

Published
2021
Full Text
View/download PDF

46. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Author

Dreger, Peter, primary, Schubert, Maria-Luisa, additional, Holtick, Udo, additional, Subklewe, Marion, additional, Bastian, von Tresckow, additional, Ayuk, Francis A., additional, Wagner, Eva Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Borchmann, Peter, additional, Rejeski, Kai, additional, Hanoun, Christine, additional, Lengerke, Claudia, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Kröger, Nicolaus, additional, and Bethge, Wolfgang A, additional

Published
2021
Full Text
View/download PDF

47. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Author

Bornhaeuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Rollig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Haenel, Mathias, additional, Mueller, Lutz Peter, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich W., additional, Roesler, Wolf, additional, Schaefer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2021
Full Text
View/download PDF

48. The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Author

Fischer, Luca, primary, Jiang, Linmiao, additional, Bittenbring, Joerg, additional, Hübel, Kai, additional, Schmidt, Christian, additional, Duell, Johannes, additional, Metzner, Bernd, additional, Krauter, Jürgen, additional, Glass, Bertram, additional, Hüttmann, Andreas, additional, Schaefer-Eckart, Kerstin, additional, Klapper, Wolfram, additional, Hiddemann, Wolfgang, additional, Unterhalt, Michael, additional, Dreyling, Martin H., additional, and Hoster, Eva, additional

Published
2021
Full Text
View/download PDF

49. Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study

Author

Mussetti, Alberto, primary, Kanate, Abraham S., additional, Wang, Tao, additional, He, Meilun, additional, Hamadani, Mehdi, additional, Finel, Hervé, additional, Boumendil, Ariane, additional, Glass, Bertram, additional, Castagna, Luca, additional, Blaise, Didier, additional, Marsh, Steven G.E., additional, Paczesny, Sophie, additional, Gadalla, Shahinaz M., additional, Dreger, Peter, additional, Spellman, Stephen R., additional, Lee, Stephanie J., additional, Bolon, Yung-Tsi, additional, and Sureda, Anna, additional

Published
2021
Full Text
View/download PDF

50. Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Author

Bethge, Wolfgang A, primary, Martus, Peter, additional, Schmitt, Michael, additional, Holtick, Udo, additional, Borchmann, Peter, additional, Subklewe, Marion, additional, Rejeski, Kai, additional, von Tresckow, Bastian, additional, Ayuk, Francis A., additional, Kroeger, Nicolaus, additional, Wagner-Drouet, Eva-Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Lengerke, Claudia, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results